Ezetimibe
Brand names: Ezetimibe, Zetia
At a glance
- Medicare prescriptions, 2024
- 8,016,770
- Medicare drug cost
- $191.8M
- Average cost per prescription
- $23.92
- Clinicians who prescribed it
- 155,035
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ZETIA ® is indicated: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ZETIA is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.
From the FDA-approved prescribing information (label dated November 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 24.2%
- Internal Medicine 23.6%
- Cardiology 18.9%
- Nurse Practitioners 15.0%
- Interventional Cardiology 6.1%
- Physician Assistants 5.1%
- Endocrinology & Diabetes 1.8%
- General Practice 1.6%
- Geriatric Medicine 0.9%
- Cardiac Electrophysiology 0.4%
- Nephrology (Kidney) 0.4%
- Heart Failure & Transplant Cardiology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 121% from 2019 to 2024.
Biggest change by state since 2019
- Idaho +194%
- Minnesota +185%
- Washington +181%
- Florida +169%
- Nevada +161%
- West Virginia (smallest change) +75%
- Kentucky (smallest change) +84%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 8 mm | SG 379 |
Marlex Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 8 mm | OP 70 |
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg / 10 mg simvastatin | white capsule, 8 mm | G321 |
| 10 mg / 20 mg simvastatin | white capsule, 11 mm | G322 |
| 10 mg / 40 mg simvastatin | white capsule, 14 mm | G323 |
| 10 mg / 80 mg simvastatin | white capsule, 17 mm | G324 |
Organon LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 8 mm | 414 |
Safecor Health, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white capsule, 9 mm | 773 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.